Table 2.
Differences in the prevalence of insulin resistance measured by HOMA-IR, HOMA-AD and L/A divided according to VAT, SAT, VAT/SAT ratio and WHR.
| VAT ≤120 cm2 n = 31 |
VAT >120 cm2 n = 25 |
p-Value * | SAT ≤225 cm2 n = 47 |
SAT >225 cm2 n = 9 |
p-Value * | VAT/SAT ≤0.9 n = 9 |
VAT/SAT >0.9 n = 29 |
p-Value* | WHR <0.85 n = 35 |
WHR ≥0.85 n = 21 |
p-Value * | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HOMA-IR ≥ 2.5 | 1.79% | 17.86% | 0.002 | 12.50% | 7.14% | NS | 0.0% | 19.64% | <0.001 | 5.36% | 14.29% | 0.013 |
| HOMA-AD ≥ 6.26 | 3.57% | 35.71% | <0.001 | 26.79% | 12.50% | 0.021 | 0.0% | 39.29% | <0.001 | 16.07% | 23.21% | 0.013 |
| L/A > 2.2 | 5.36% | 39.29% | <0.001 | 30.36% | 14.29% | 0.007 | 5.36% | 39.29% | <0.001 | 12.50% | 32.14% | <0.001 |
* The differences were analyzed with Fisher’s exact test; p < 0.05. Abbreviations: VAT—visceral fat surface; SAT—subcutaneous fat surface; VAT/SAT—visceral to subcutaneous fat ratio; WHR—waist-to-hip ratio; HOMA-IR—homeostatic model assessment of insulin resistance; HOMA-AD—homeostatic model assessment—adiponectin; L/A—leptin to adiponectin ratio; NS—not statistically significant.